HIV-1 drug resistance at virological failure versus immunological failure among patients failing first-line antiretroviral therapy in a resource-limited setting

International Journal of STD and AIDS

Volumn 23, Issue 5, 2012, Pages 316-318

  Sungkanuparph, S ^a   Win, M M ^b   Kiertiburanakul, S ^a   Phonrat, B ^b   Maek a nantawat, W ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Antiretroviral therapy; Genotypes; HIV 1; Immunological failure; Monitoring; Mutations; Resistance; Treatment failure; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOLOGICAL FAILURE; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; VIROLOGICAL FAILURE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 84861786715     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2011.011337     Document Type: Article

References (22)

1. World Health Organization. Towards Universal Access Scaling up Priority HIV/AIDS Interventions in the Health Sector. Progress report, 2010. WHO Library Cataloguing-in-Publication Data. See http://www.who.int/hiv/pub/ 2010programreport/summary_en.pdf (last accessed 1 September 2011)
2. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/ tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006;43:42-6
3. Kumarasamy N, Solomon S, Chaguturu SK, et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis 2005;41:1525-8
4. Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr HIV Res 2007;5:355-60
5. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand. J Infect 2006;52:188-94
6. Zhou J, Paton NI, Ditangco R, et al. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med 2007;8:8-16
7. Thompson MA, Aberg JA, Cahn P, et al. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304:321-33
8. Aberg JA, Kaplan JE, Libman H, et al. HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009;49:651-81
9. Gazzard BG, Anderson J, Babiker A, et al. BHIVA Treatment Guidelines Writing Group. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563-608
10. Sungkanuparph S, Anekthananon T, Hiransuthikul N, et al. Thai AIDS Society. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai 2008;91:1925-35
11. World Health Organization. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. November 2009; 1-24. See http://www. who.int/hiv/pub/arv/rapid_advice_art.pdf (last checked 7 September 2011)
12. Ministry of Health & Family Welfare, Government of India. Antiretroviral Therapy Guidelines for HIV-Infected Adults and Adolescents Including Post-Exposure Prophylaxis. India, 2007. See http://www.nacoonline.org/NACO (last checked 7 September 2011)
13. Mee P, Fielding KL, Charalambous S, et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008;22:1971-7
14. Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis 2008;8:89
15. Kantor R, Diero L, Delong A, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009;49:454-62
16. Grant RM, Kuritzkes DR, Johnson VA, et al. Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol 2003;41:1586-93
17. Kuritzkes DR, Grant RM, Feorino P, et al. Performance characteristics of the TRUGENE HIV-1 Genotyping kit and the Opengene DNA Sequencing System. J Clin Microbiol 2003;41:1594-9
18. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010;18:156-63
19. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007;44:447-52
20. Mbisa JL, Gupta RK, Kabamba D, et al. The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains. Retrovirology 2011;8:31
21. Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, et al. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS 2003;17:1889-96
22. Scherrer AU, von Wyl V, Joos B, et al. Swiss HIV Cohort Study. Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study. J Infect Dis 2011;203:791-7